Clinical Trials Logo

Pulmonary Heart Disease clinical trials

View clinical trials related to Pulmonary Heart Disease.

Filter by:

NCT ID: NCT04879069 Recruiting - Clinical trials for Pulmonary Embolism With Acute Cor Pulmonale

Polish Multicenter PERTs PE Outcomes Registry

PolPERTs
Start date: June 1, 2018
Phase:
Study type: Observational

Pulmonary embolism (PE) is the third leading cause of cardiovascular mortality. The Pulmonary Embolism Response Team (PERT) concept offers a rapid and multidisciplinary approach focused on improving outcomes for patients with PE. All institutionalized PERTs in Poland have been invited to join the study. The goal of this registry is to describe current practice and outcomes in patients with acute PE treated by Polish PERTs.

NCT ID: NCT04865640 Completed - Clinical trials for Cardiopulmonary Disease

Clinical Validation Study for Noninvasive Cardiopulmonary Management Device

Start date: November 19, 2020
Phase:
Study type: Observational

The ADI At-Home CPM (Cardiopulmonary Management) System is a non-invasive device that measures and trends a variety of biological parameters. This study will be conducted as a prospective non-randomized study with two study arms/cohorts - one of healthy adult patients, one of pathologic patients who fit into the intended use population of the CPM System.

NCT ID: NCT04863677 Recruiting - Clinical trials for Myocardial Infarction

The Effect of HIIT, MICT in Patients With Myocardial Infarction

Start date: May 1, 2021
Phase: N/A
Study type: Interventional

This study will investigate the effect of a 12-weeks cardiac rehabilitation training (HIIT, MICT) program on VO2peak and cardiac fibrosis in patients, and evaluate the effects of HIIT on endothelial function, microvascular obstruction, body fat, inflammation, arrhythmia and psychology .

NCT ID: NCT04859894 Recruiting - Covid19 Clinical Trials

Physiological Studies in Post-COVID-19 Syndrome, and the Association With DNA Methylation

Start date: April 20, 2021
Phase:
Study type: Observational

The physiological derangements in subjects suffering from long-term symptoms following a Covid-19 infection (Post-COVID-19 Syndrome) are poorly understood and evaluated. This study will recruit subjects with a clinical diagnosis of Post-Covid-19-syndrome) who are scheduled for either of lung function testing, cardiopulmonary exercise testing or cardiac ultrasound. Patients' symptoms will be correlated to physiological measures and compared to predicted values. In addition, in 20 patients, symptoms and physiological measures will be correlated to epigenetical alterations, or DNA-methylation patterns. In addition, a subset of patients will be examined a year after the baseline testing in order to follow the progress of the disease.

NCT ID: NCT04844307 Withdrawn - COVID-19 Clinical Trials

Comparing Inpatient COVID-19 Outcomes in 2 Different PT Dosing Groups

CCPT
Start date: October 2021
Phase: N/A
Study type: Interventional

The objective of this study is to compare the effects of twice-a-day 15-minute sessions of inpatient physical therapy (PT) to the standard daily 30 minute sessions. The patient outcomes that will be evaluated will be length of stay, change in functional status, and disposition (home/acute rehab vs. subacute/LTAC/death) in patients admitted with COVID-19.

NCT ID: NCT04825067 Recruiting - Asthma Clinical Trials

Remote Monitoring of High-Risk Patients With Chronic Cardiopulmonary Diseases

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

In this project, Institute of Bioengineering & Bioimaging (IBB), A*STAR would like to collaborate with Massachusetts General Hospital to aggregate patient data and to further develop its software algorithm using machine learning and statistical models for predicting exacerbations and deterioration on 60 patients with cardiopulmonary diseases.

NCT ID: NCT04628195 Completed - Covid19 Clinical Trials

Cardiac Performance in Mechanically Ventilated COVID-19 Patients

Start date: April 1, 2020
Phase:
Study type: Observational

Although COVID-19 affects primarily the respiratory system, several studies have shown evidence of cardiovascular alterations. Increased troponin levels were observed in a significant proportion of patients and this alteration was associated with higher mortality. In addition, case reports of cardiogenic shock or fulminant myocarditis have been communicated. Likewise, pulmonary embolism (PE), right ventricle dilation, and acute cor pulmonale (ACP) have also been described. Therefore, investigating cardiac function in COVID-19 is highly relevant, particularly in critically ill patients who are usually under sedation and mechanical ventilation, which may further impair cardiovascular function. Thus the objective is to determine the prevalence of left ventricle dysfunction and acute cor pulmonale, and its association with respiratory mechanics, in 100 consecutive critically ill COVID-19 patients, who were assessed with critical care echocardiography (CCE) within the first 24 hours of mechanical ventilation.

NCT ID: NCT04473560 Recruiting - Clinical trials for Pulmonary Embolism With Acute Cor Pulmonale

Catheter-directed Thrombectomy in High and Intermediate-high Risk Pulmonary Embolism

CATH-PE
Start date: October 1, 2018
Phase:
Study type: Observational [Patient Registry]

Pulmonary embolism is one of the leading causes of cardiovascular death. Pulmonary embolism may be life-threatening condition with an estimated 30-day mortality rate about 10-30%. In high-risk pulmonary embolism, systemic thrombolysis is indicated, whereas recent development of interventional cardiology has made catheter-directed techniques an important alternative to thrombolytic therapy. The controversy concerns also risk stratification and treatment in intermediate-high risk pulmonary embolism patients. A significant percentage of intermediate-high risk patients with pulmonary embolism may experience rapid hemodynamic deterioration and then the prognosis in this group is significantly worse. Catheter-directed techniques are aimed to quickly relive obstruction and restore pulmonary blood flow, thus increasing cardiac output and immediately restoring hemodynamic stability. The scope of this study is to evaluate the safety and feasibility of catheter-directed approaches in high-risk and intermediate-high risk pulmonary embolism patients.

NCT ID: NCT04112420 Recruiting - Clinical trials for Intensive Care Unit Syndrome

Detection of the Incidence of Pre-existing Cardio-pulmonary Diseases by Using of Echocardiography

Start date: October 1, 2019
Phase: N/A
Study type: Interventional

Introduction: The uncomplicated and focused transthoracic cardiac ultrasound examination, which is gentle for the patient, gives the doctor in a short time a lot of information about possible, as unrecognized pathologies of the organs of the chest. Before a patient undergoes a planned procedure or intervention with a subsequent intensive stay, examinations are necessary from which the anesthetist/intensive physician has important information the state of health of the patient. The findings and the information will be used to plan the individual anesthesia procedures and intensive medical management, which is suitable for the patient. The aim of this work is to investigate whether the use of a modified examination protocol in patients who need to be admitted to an intensive care unit has an influence on the actions of the intensive care physician. Does the information that is collected from the findings have a complementary influence in the planning of intensive care management? The Study objectives Primary objectives: What is the frequency with which pathological changes are detected? Secondary objectives: Do the additional findings have an influence on the intensive care procedure?

NCT ID: NCT03988842 Terminated - Pulmonary Embolism Clinical Trials

Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism

SAFE-LYSE
Start date: July 25, 2019
Phase: Phase 4
Study type: Interventional

The purpose of this study is to examine the degree to which pulmonary embolism (clot) can be dissolved when treated with a very low dose of a systemic thrombolytic drug (clot buster) along with standard anticoagulant therapy as compared to the standard of care anticoagulant therapy alone.